Vernakalant for the conversion of atrial fibrillation: The new kid on the block?

Guardado en:
Detalles Bibliográficos
Autores principales: Conde, D., Baranchuk, A.
Formato: JOUR
Materias:
atrial fibrillation
pharmacological cardioversion
vernakalant
anisole derivative
antiarrhythmic agent
pyrrolidine derivative
bradycardia
cardiogenic shock
cardioversion
drug safety
heart atrium fibrillation
human
hypotension
patient safety
priority journal
review
sinus rhythm
Atrial Fibrillation
randomized controlled trial (topic)
Anisoles
Anti-Arrhythmia Agents
Humans
Pyrrolidines
Randomized Controlled Trials as Topic
Acceso en línea:http://hdl.handle.net/20.500.12110/paper_1082720X_v19_n4_p299_Conde
Aporte de:
Biblioteca Digital - Facultad de Ciencias Exactas y Naturales (UBA) de Universidad de Buenos Aires
Descripción
Descripción no disponible.

Ejemplares similares